



COLLEGE of AMERICAN
PATHOLOGISTS

November 16, 2024

National Government Services
Medical Policy Unit
P.O. Box 7108
Indianapolis, IN 46207-7108
NGSDraftLCDComments@anthem.com

RE: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases (DL37606).

Dear Dr. Boren and Dr. Duerden:

Thank you for the opportunity to review and comment on the proposed updates to your coverage policy for Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases (DL37606). As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide.

Molecular oncology experts from the CAP have reviewed the proposed genomic biomarker updates for acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN), and agree that the updates in the draft are appropriate and that the specified genes and genetic alterations are medically necessary for each condition. We further support NGS' decision to broaden coverage to include genomic sequential analysis panel testing for all newly diagnosed or relapsed/refractory AML patients who are candidates for treatment, regardless of karyotype findings. We believe that the updates to this policy will ensure patients have access to the molecular testing necessary to guide their treatment.

Thank you again for the opportunity to review and comment on this proposed policy. We are happy to be of assistance in providing additional information to assist you with this draft LCD if needed. Please direct your correspondence to Nonda Wilson, CAP's Manager of Economic and Regulatory Affairs, at nwilson@cap.org.

Sincerely,

College of American Pathologists